Financial Comparison: Palladyne AI (NASDAQ:PDYN) vs. Mainz Biomed (NASDAQ:MYNZ)

Palladyne AI (NASDAQ:PDYN) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Risk & Volatility

Palladyne AI has a beta of 3.67, suggesting that its share price is 267% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Earnings and Valuation

This table compares Palladyne AI and Mainz Biomed”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palladyne AI	$5.25 million	55.22	$10.04 million	($0.68)	-8.64
Mainz Biomed	$659,935.00	19.08	-$21.65 million	($65.60)	-0.02

Palladyne AI has higher revenue and earnings than Mainz Biomed. Palladyne AI is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Palladyne AI and Mainz Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palladyne AI	-254.75%	-53.29%	-40.05%
Mainz Biomed	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Palladyne AI and Mainz Biomed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palladyne AI	1	2	3	0	2.33
Mainz Biomed	1	1	0	0	1.50

Palladyne AI presently has a consensus price target of $11.00, indicating a potential upside of 87.20%. Given Palladyne AI’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Palladyne AI is more favorable than Mainz Biomed.

Institutional and Insider Ownership

26.0% of Palladyne AI shares are owned by institutional investors. 13.4% of Palladyne AI shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Palladyne AI beats Mainz Biomed on 9 of the 14 factors compared between the two stocks.

About Palladyne AI

Palladyne AI Corp., a software company, focuses on delivering software that enhances the utility and functionality of third-party stationary and mobile robotic systems in the United States. Its Artificial Intelligence (AI)/ Machine Learning (ML) software platform enables robots to observe, learn, reason, and act in structured and unstructured environments. The company's software platform enables robotic systems to perceive their environment and quickly adapt to changing circumstances by generalizing from their experience using dynamic real-time operations without extensive programming and with minimal robot training. It serves customers from various industries, such as industrial manufacturing, warehousing and logistics, defense, infrastructure maintenance and repair, energy, aerospace and aviation, and others. The company was formerly known as Sarcos Technology and Robotics Corporation and changed its name to Palladyne AI Corp. in March 2024. Palladyne AI Corp. was founded in 2017 and is headquartered in Salt Lake City, Utah.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.